These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25449689)

  • 1. Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
    Liedtke M; Dunn T; Dinner S; Coutré SE; Berube C; Gotlib J; Patel S; Medeiros B
    Leuk Res; 2014 Dec; 38(12):1441-5. PubMed ID: 25449689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
    Ahn JS; Yang DH; Jung SH; Lee JJ; Kim I; Park S; Chung JS; Shin HJ; Kim DY; Lee KH; Moon JH; Sohn SK; Song IC; Jo DY; Joo YD;
    Acta Haematol; 2015; 133(1):91-7. PubMed ID: 25171064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
    Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; Alizadeh AA; Medeiros BC
    Am J Hematol; 2010 Nov; 85(11):877-81. PubMed ID: 20872554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
    Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
    Mariańska B; Apel D; Seferyńska I; Maj S
    Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
    Raanani P; Shpilberg O; Gillis S; Avigdor A; Hardan I; Berkowicz M; Sofer O; Lossos I; Chetrit A; Ben-Yehuda D; Ben-Bassat I
    Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
    Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
    Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
    Trifilio SM; Rademaker AW; Newman D; Coyle K; Carlson-Leuer K; Mehta J; Altman J; Frankfurt O; Tallman MS
    Leuk Res; 2012 Apr; 36(4):394-6. PubMed ID: 22172465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy].
    Uzuka Y; Saito Y; Takahashi H; Komatsu M; Ito T; Toyota T
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1917-23. PubMed ID: 2393309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
    Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
    Milpied N; Gisselbrecht C; Harousseau JL; Sebban C; Witz F; Troussard X; Gratecos N; Michallet M; LeBlond V; Auzanneau G
    Cancer; 1990 Aug; 66(4):627-31. PubMed ID: 2386891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.